edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Pharnext
Edison Investment Research is terminating coverage on Pharnext (ALPHA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Pharnext — 1 video in collection
In this interview we speak to David Solomon, CEO of Pharnext, a Euronext Paris-listed company developing medicines for neurological disorders based on its Pleotherapy platform, which unearths new therapeutic effects from drug combinations. Its lead program is PXT3003 for Charcot-Marie-Tooth disease, which is entering Phase III.
Get access to the very latest content matched to your personal investment style.